 |
|
A Novel Organ Preservation Protocol for Advanced Carcinoma of the Larynx and Pharynx
K. Thomas Robbins, MD;
James Fontanesi, MD;
Frank S. H. Wong, MD;
Daniel Vicario, MD;
Stephen Seagren, MD;
Parvesh Kumar, MD;
Robert Weisman, MD;
Phillip Pellitteri, DO;
J. Randal Thomas, MD;
Pamela Flick, MD;
Robert Palmer, MD;
Alva Weir, III, MD;
Charles Kerber, MD;
Thomas Murry, PhD;
Robert Ferguson, MD;
Gerritt Los, PhD;
Lisa Orloff, MD;
Stephen B. Howell, MD
Arch Otolaryngol Head Neck Surg. 1996;122(8):853-857.
Abstract
| |
Objective
To pilot a targeted chemoradiation protocol for patients with advanced carcinoma of the larynx and pharynx that would circumvent upper aerodigestive tract dysfunction related to major oncologic surgery.
Design
Weekly intra-arterial infusions of supradose cisplatin (150 mg/m2 per week x4) rapidly delivered to the tumor bulk, simultaneous intravenous sodium thiosulfate for systemic drug neutralization, and conventional external-beam irradiation (1.80-2.00 Gy per fraction x35) were used. Between February 1991 and April 1994, 42 patients were treated who would otherwise have required a major resection of the tongue base, pharyngeal wall, or larynx.
Main Outcome Measures
Tumor response, toxic effects, disease control above the clavicle, preservation of the larynx, maintenance of oral nutrition, and overall and disease-related 2-year survival.
Results
Three complications were related to the weekly transfemoral superselective intra-arterial procedures performed 160 times. Grade 3 to 4 chemotoxic effects were infrequent, occurring in 9 (5.5%) of 160 cycles, and only 1 patient required a radiotherapy break because of severe mucositis. A complete response in the primary site was obtained in 36 (86%) of 42 patients, 2 of whom had residual disease in the neck. Median follow-up was 13 months (range, 3-46 months). To date, there have been 5 recurrences: 2 regional and 3 distant. The 2-year overall and disease-related survival was 64% and 76%, respectively. The rate of disease control above the clavicle at 2 years was 86%.
Conclusions
We believe this chemoradiation protocol represents an effective management scheme for patients with advanced head and neck cancer while minimizing dysfunction and possibly improving survival.
Arch Otolaryngol Head Neck Surg. 1996;122:853-857
Author Affiliations
From the Department of Otolaryngology—Head and Neck Surgery (Drs Robbins, Wong, and Murry), Department of Radiology (Drs Fontanesi, Kumar, Flick, Palmer, and Ferguson), and Division of Hematology-Oncology (Drs Thomas and Weir), University of Tennessee School of Medicine, Memphis; and Division of Otolaryngology—Head and Neck Surgery, Department of Surgery (Drs Weisman, Pellitteri, Los, and Orloff), Division of Hematology and Oncology, Department of Medicine (Drs Vicario and Howell), and Division of Radiation Oncology, Department of Radiology (Drs Seagren and Kerber), School of Medicine and the Cancer Center, University of California, San Diego.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Prevention of Hearing Loss in Children Receiving Cisplatin Chemotherapy
Freyer et al.
JCO 2009;27:317-318.
FULL TEXT
A Cone-Beam Volume CT Using a 3D Angiography System with a Flat Panel Detector of Direct Conversion Type: Usefulness for Superselective Intra-arterial Chemotherapy for Head and Neck Tumors
Kakeda et al.
Am. J. Neuroradiol. 2007;28:1783-1788.
ABSTRACT
| FULL TEXT
RADPLAT: An Alternative to Surgery?
Alkureishi et al.
The Oncologist 2006;11:469-480.
ABSTRACT
| FULL TEXT
Long-term Quality of Life for Surgical and Nonsurgical Treatment of Head and Neck Cancer
El-Deiry et al.
Arch Otolaryngol Head Neck Surg 2005;131:879-885.
ABSTRACT
| FULL TEXT
Intra-arterial Cisplatin and Concomitant Radiation Therapy Followed by Surgery for Advanced Paranasal Sinus Cancer
Samant et al.
Arch Otolaryngol Head Neck Surg 2004;130:948-955.
ABSTRACT
| FULL TEXT
Voice and Swallowing in Patients Enrolled in a Larynx Preservation Trial
Carrara-de Angelis et al.
Arch Otolaryngol Head Neck Surg 2003;129:733-738.
ABSTRACT
| FULL TEXT
Long-term Survival Outcome in Transhyoid Resection of Base of Tongue Squamous Cell Carcinoma
Azizzadeh et al.
Arch Otolaryngol Head Neck Surg 2002;128:1067-1070.
ABSTRACT
| FULL TEXT
The Ascending Pharyngeal Artery: Branches, Anastomoses, and Clinical Significance
Hacein-Bey et al.
Am. J. Neuroradiol. 2002;23:1246-1256.
ABSTRACT
| FULL TEXT
Concomitant Chemoradiotherapy in Pyriform Sinus Carcinoma
Prades et al.
Arch Otolaryngol Head Neck Surg 2002;128:384-388.
ABSTRACT
| FULL TEXT
Analysis of Risk Factors Predictive of Distant Failure After Targeted Chemoradiation for Advanced Head and Neck Cancer
Doweck et al.
Arch Otolaryngol Head Neck Surg 2001;127:1315-1318.
ABSTRACT
| FULL TEXT
High-Dose Intra-arterial Cisplatin Therapy Followed by Radiation Therapy for Advanced Squamous Cell Carcinoma of the Head and Neck
Wilson et al.
Arch Otolaryngol Head Neck Surg 2001;127:809-812.
ABSTRACT
| FULL TEXT
The Evolving Role of Combined Modality Therapy in Head and Neck Cancer
Robbins
Arch Otolaryngol Head Neck Surg 2000;126:265-269.
FULL TEXT
Efficacy of Targeted Chemoradiation and Planned Selective Neck Dissection to Control Bulky Nodal Disease in Advanced Head and Neck Cancer
Robbins et al.
Arch Otolaryngol Head Neck Surg 1999;125:670-675.
ABSTRACT
| FULL TEXT
Aggressive Concurrent Chemoradiotherapy for Squamous Cell Head and Neck Cancer: An 8-Year Single-Institution Experience
Lavertu et al.
Arch Otolaryngol Head Neck Surg 1999;125:142-148.
ABSTRACT
| FULL TEXT
Eating and Weight Changes Following Chemoradiation Therapy for Advanced Head and Neck Cancer
Newman et al.
Arch Otolaryngol Head Neck Surg 1998;124:589-592.
ABSTRACT
| FULL TEXT
|
